Biogen Issued CRL (complete response letter) for Subcutaneous Natalizumab in Relapsing MS
Just weeks after receiving an EU marketing authorization, the FDA has issued a complete response letter to Biogen for its…
Biogen and Capsigen Collaborate to Develop New AAV Capsids for CNS, Neuromuscular Disorders
May 11, 2021 – by: Victoria Johnson The partnership combines Capsigen’s vector engineering with Biogen’s drug pipeline, seeking to…
Stuart Schlossman
Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients
Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive of multiple sclerosis (MS),…
Stuart Schlossman
COVID-19 in ocrelizumab-treated people with multiple sclerosis
Abstract Background: There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory…
Stuart Schlossman
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian…
Stuart Schlossman
Black MS Patients See More Rapid B-Cell Repopulation
May have implications for timing of lab draws and anti-CD20 dosing, researchers say by Ed Susman, Contributing Writer, MedPage Today April 20, 2021…
Stuart Schlossman
Study: Black People May Respond Differently to Common MS Therapy than White People
NEWS PROVIDED BY American Academy of Neurology Apr 16, 2021, 07:02 ET MINNEAPOLIS, April 16, 2021 /PRNewswire/ — A preliminary study suggests that…
Stuart Schlossman
Helper T-cells Drive Transition from RRMS to SPMS, Study Suggests
April 2021 A group of helper T-cell (Th cells), a type of immune cell, could be responsible for the transition…
Stuart Schlossman
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of …
ROCKLAND, Mass.–(BUSINESS WIRE)–Apr 16, 2021– EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada,…
Stuart Schlossman
Elevated Serum GFAP Predicts MS-Associated Diffuse White Matter Damage
March 26, 2021 In this study, patients with MS with relapsing remitting or secondary progressive disease underwent diffusion tension imaging…
Stuart Schlossman
